Screener
Nektar Therapeutics NKTR Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $763,271 | $280,406 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable (including $504 and $137 as of March 31, 2026 and December 31, 2025, respectively, to a related party) | $10,026 | $10,770 |
| Accrued expenses (including $1,148 and $994 as of March 31, 2026 and December 31, 2025, respectively, to a related party) | 25,151 | 22,271 |
| Operating lease liabilities, current portion | 22,531 | 20,495 |
| Total current liabilities | 57,708 | 53,536 |
| Operating lease liabilities, less current portion | 60,631 | 65,256 |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's accounts payable?
- Nektar Therapeutics (NKTR) reported accounts payable of $10.03M in Q1 2026.
- How has Nektar Therapeutics's accounts payable changed year-over-year?
- Nektar Therapeutics's accounts payable decreased by 43.8% year-over-year, from $17.83M to $10.03M.
- What is the long-term trend for Nektar Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Nektar Therapeutics's accounts payable has grown at a -13.4% compound annual growth rate (CAGR), from $22.14M to $10.77M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Nektar Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude